glp 1 agonist and depression Prevalence of GLP-1 Receptor Use Among Privately Insured Individuals With Mood Disorders Glucagon-like Peptide-1 receptor agonists as
Description
Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat
59% were males
Plan durations vary by medication type and include 3-, 6-, 10-, or 12-month options
Tirzepatide: nausea (40-50%), diarrhea (15-25%), constipation (10-20%), vomiting (10-15%)
Larger randomized controlled trials with clinical endpoints, focusing on both cardiovascular morbidity and mortality, should be performed to verify the cardioprotective properties of GLP-1R agonists in patients with CAD and select the population in whom it will be most effective
Lancet 2020;395:709-33.PubMedPMC 5
